What Does a Bethesda 4 Thyroid Nodule Result Mean?

A Bethesda 4 thyroid nodule is one whose fine-needle aspiration (FNA) sample was reported as follicular neoplasm, sometimes written as suspicious for follicular neoplasm (FN/SFN). It means the cells came from a growth made of thyroid follicular cells, and the needle sample cannot tell whether that growth is benign or cancerous. Most of these nodules are not cancer, and the usual next step is a discussion about surgery or molecular testing to get a clearer answer.

The Bethesda system has six categories for thyroid FNA reports: nondiagnostic, benign, atypia of undetermined significance (AUS), follicular neoplasm, suspicious for malignancy and malignant. Category 4 is one of the in-between, or indeterminate, results.

This guide is for adults who have received a Bethesda 4 report. It explains the terms and choices to help you talk with your care team; it cannot interpret your own result.

A Bethesda 4 result is not an emergency in itself. Some symptoms need prompt attention regardless. The NHS advises seeking urgent medical help if you have difficulty breathing or are more short of breath than usual. If breathing becomes very difficult, call your local emergency number.

Contact your clinician sooner rather than waiting for your planned appointment if you notice:

• A neck lump that is getting bigger, or new pain or a feeling of pressure in the front of the neck.
• A hoarse voice or difficulty swallowing that is not getting better.
• After the biopsy: fever, chills, or redness, swelling or pus at the needle site, which Cleveland Clinic lists as possible signs of infection.

A needle sample shows individual cells and small clusters. For follicular growths, benign and cancerous nodules can look very alike at that level. Cleveland Clinic explains that with a follicular neoplasm result it is hard to tell whether the nodule is benign or cancerous unless it is surgically removed. The American Thyroid Association (ATA) patient page likewise says surgery is the only way to confirm the diagnosis.

Once the whole nodule is removed, the pathologist can examine all of it rather than a small sample of cells. That is why the operation is often described as diagnostic surgery.

Cleveland Clinic states that about 15% to 30% of follicular neoplasm nodules are cancerous. The 2015 ATA guideline gives the same predicted range, and the ATA patient page gives a figure of 20% to 30%. Put the other way round, most of these nodules turn out to be benign.

These are averages from groups of patients, and estimates differ between laboratories and over time. They are not a prediction for one person. Your team will consider the ultrasound appearance, nodule size and your history alongside the number.

It can help to keep the wider picture in mind. The National Cancer Institute notes that thyroid nodules are common but usually are not cancer, and only a small number are diagnosed as cancer. A Bethesda 4 result raises a question that needs answering; it does not answer it. Waiting for an appointment or test result can be stressful, so ask your team who to contact with questions in the meantime.

The ATA guideline describes diagnostic surgical removal as the long-established standard of care for follicular neoplasm results. When surgery is considered for a single indeterminate nodule, it recommends a lobectomy, removing the half of the thyroid that contains the nodule, as the usual first operation. The ATA patient page notes that, because most of these nodules are not cancer, usually only the affected side is removed.

If the removed nodule is benign, the team will explain any follow-up needed. If it shows cancer, the team will explain whether anything more is needed; the ATA guideline notes that a second operation to remove the rest of the thyroid may be needed in some cases.

The ATA thyroid surgery page lists the main risks. It gives a 5–7% risk of temporary hoarseness and a 0.5% risk of permanent injury to the voice nerve, and says lobectomy carries no risk of low calcium. The remaining half of the thyroid may keep hormone levels normal, but some people still need thyroid hormone tablets afterwards.

Sometimes. The ATA guideline says that after considering clinical and ultrasound features, molecular testing may be used to add to the risk assessment instead of going straight to surgery, and that informed patient preference and feasibility should be considered. If molecular testing is not done or is inconclusive, surgery may be considered for removal and a definite diagnosis.

Molecular tests look for gene changes or patterns in the cells from the FNA sample. The ATA guideline notes that different tests are better at either ruling cancer out or pointing towards it, and no single test is perfect. Availability and cost vary by country and health service.

Ask which test is available, how a result would change your plan and what happens if it comes back unclear.

Bring the cytology report, the ultrasound report and a list of your medicines. These questions can help you reach a decision you understand.

• What did my ultrasound show, and does anything about the nodule change your level of concern?
• Is molecular testing available and suitable for my nodule, and would it change your advice?
• If you recommend a lobectomy, what are the risks for me, and how likely is it that I will need thyroid hormone afterwards?
• What would happen if the removed nodule shows cancer?
• How experienced is the surgical team in thyroid operations, and could a pathologist experienced in thyroid cancer review my slides, as the National Cancer Institute suggests patients can ask?
• If I want more time to decide, what is a reasonable timeframe, and what should prompt me to call sooner?

On SameCase, patients and verified doctors share de-identified cases. Seeing how others with a Bethesda 4 result weighed molecular testing against lobectomy, or what their recovery was like, can help you think of practical questions for your own appointment.

Other people's cases cannot diagnose your nodule or predict your outcome. Use them to prepare questions, and make decisions with your own care team.